Rare case of apatinib acquired resistance induced by point mutation of WRN p.V697F through activation of the PI3K/AKT apoptosis‐inhibiting pathway

Targeted therapy has become the main treatment for non‐small cell lung cancer (NSCLC). Apatinib is a new antiangiogenic antitumor drug developed in China which targets vascular endothelial growth factor receptor‐2 (VEGFR‐2). We recently treated a 50‐year‐old female patient who underwent a bronchosco...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ruofei, Bai, Hua, Gao, Bingyu, Li, Tangai, He, Xiran, Zhang, Pei, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779201/
https://www.ncbi.nlm.nih.gov/pubmed/33225619
http://dx.doi.org/10.1111/1759-7714.13726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779201/
https://www.ncbi.nlm.nih.gov/pubmed/33225619
http://dx.doi.org/10.1111/1759-7714.13726

Ejemplares similares